Jefferies on Denali (DNLI): 'Net-net, we remain 70-80%+ confident in an FDA approval by the April 5, 2026 PDUFA date'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $40.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
